Heart failure & cardiomyopathiesResearch article
Deterministic Economic Modelling Study of Tafamidis in Transthyretin Amyloid Cardiomyopathy Across Four European Healthcare Systems
- deterministic modelling study
- case-scenarii based on various assumptions
- sensitivity analysis
Authors' conclusion
While tafamidis offers a significant improvement in patients’ quality of life and survival, these exploratory scenario-based estimates showing high cost-effectiveness ratio in some European countries, may raise public health and cost management concerns.
Study context
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in France, Spain, Germany and the United Kingdom (UK)
- Comparison
- incremental cost-effectiveness ratio (ICER) of tafamidis compared with standard care
Main finding
As reported in the abstract
Incremental cost-effectiveness ratio (ICER)
France
€398,136/QALY gained
Germany
€1,398,706/QALY gained
Further findings
Sensitivity analysis: probability of cases below the acceptability threshold of €100,000/QALY
- France
- 27.4%
- Spain
- 0.2%
- Germany
- 13%
- UK
- 9%
- Large variations of the ICER
Original publication
Deterministic Economic Modelling Study of Tafamidis in Transthyretin Amyloid Cardiomyopathy Across Four European Healthcare Systems. Eur Heart J Qual Care Clin Outcomes. Published 18 August 2026. doi:10.1093/ehjqcco/qcag129
Summarised from the published abstract; every number is checked against it